KalVista Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
KalVista Pharmaceuticals's earnings have been declining at an average annual rate of -33.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 76% per year.
Key information
-33.9%
Earnings growth rate
-20.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -76.0% |
Return on equity | -122.3% |
Net Margin | n/a |
Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
No updates
Recent updates
KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Feb 14We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Jan 30We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Oct 04We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
May 02KalVista: Another Setback But The Key Value Driver Is Still In Place
Oct 14Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
Sep 24KalVista Pharmaceticals GAAP EPS of -$0.94
Sep 08KalVista reaches five-month high as rival tumbles on hereditary angioedema
Aug 22KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11
Jul 07Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
May 18Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth
Feb 02We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed
Sep 24We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely
Jul 02KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study
Jun 07KalVista Pharmaceuticals names new medical chief
May 03How Much Did KalVista Pharmaceuticals' (NASDAQ:KALV) CEO Pocket Last Year?
Mar 01Estimating The Fair Value Of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Feb 03Revenue & Expenses BreakdownBeta
How KalVista Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jan 24 | 0 | -108 | 39 | 0 |
31 Oct 23 | 0 | -101 | 35 | 0 |
31 Jul 23 | 0 | -95 | 32 | 0 |
30 Apr 23 | 0 | -93 | 31 | 0 |
31 Jan 23 | 0 | -91 | 30 | 0 |
31 Oct 22 | 0 | -92 | 30 | 0 |
31 Jul 22 | 0 | -89 | 29 | 0 |
30 Apr 22 | 0 | -82 | 26 | 0 |
31 Jan 22 | 0 | -73 | 25 | 0 |
31 Oct 21 | 0 | -61 | 22 | 0 |
31 Jul 21 | 0 | -52 | 19 | 0 |
30 Apr 21 | 0 | -46 | 17 | 0 |
31 Jan 21 | 4 | -38 | 14 | 0 |
31 Oct 20 | 5 | -37 | 13 | 0 |
31 Jul 20 | 9 | -33 | 13 | 0 |
30 Apr 20 | 13 | -29 | 13 | 0 |
31 Jan 20 | 12 | -31 | 13 | 0 |
31 Oct 19 | 14 | -26 | 13 | 0 |
31 Jul 19 | 16 | -23 | 12 | 0 |
30 Apr 19 | 16 | -21 | 11 | 0 |
31 Jan 19 | 18 | -13 | 10 | 0 |
31 Oct 18 | 16 | -14 | 9 | 0 |
31 Jul 18 | 12 | -16 | 9 | 0 |
30 Apr 18 | 8 | -16 | 9 | 0 |
31 Jan 18 | 4 | -19 | 3 | 0 |
31 Oct 17 | 2 | -22 | 6 | 0 |
31 Jul 17 | 1 | -21 | 4 | 0 |
30 Apr 17 | 2 | -21 | 11 | 0 |
31 Jan 17 | 2 | -23 | 10 | 0 |
31 Oct 16 | 2 | -18 | 6 | 0 |
31 Jul 16 | 2 | -18 | 5 | 0 |
30 Apr 16 | 2 | -15 | 3 | 0 |
30 Apr 15 | 2 | -9 | 2 | 0 |
Quality Earnings: KALV is currently unprofitable.
Growing Profit Margin: KALV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KALV is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.
Accelerating Growth: Unable to compare KALV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KALV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: KALV has a negative Return on Equity (-122.26%), as it is currently unprofitable.